A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs WP 1066 (Primary)
- Indications Brain metastases; Glioblastoma; Glioma; Malignant melanoma
- Focus Adverse reactions; First in man
- 15 Feb 2018 According to a Moleculin Biotech media release, the company is planning to initiate dosing within the first half of 2018.
- 05 Dec 2017 According to a Moleculin Biotech media release, Investigational New Drug (IND) application for this trial has been approved by the US Food and Drug Administration (FDA).
- 07 Nov 2017 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.